University of Michigan Spinoff Lycera Begins First Trials Of U-M Developed & Licensed IBD Drug

University of Michigan Spinoff Lycera Begins First Trials Of U-M Developed & Licensed IBD Drug
Lycera Corp., a University of Michigan spinoff biotech firm based on campus at Ann Arbor, has begun a Phase 1 clinical trial of the Inflammatory Bowel Disease (IBD Drug) LYC-30937 in healthy volunteers. Lycera is a biopharmaceutical company focused on developing breakthrough immunomodulatory medicines for treating autoimmune diseases and cancer. The drug candidate LYC-30937 is

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *